Stockscreener 앱 받기
309.49
2.76%
8.30
시간 외 거래:
313.83
4.34
+1.40%
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Alnylam Pharmaceuticals Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
Alnylam Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Reports Strong Q1 2026 Earnings a - GuruFocus
Alnylam (ALNY) Reports Impressive Q1 Revenue Growth - GuruFocus
Alnylam’s research pact worth up to $1.1B sends Tenaya higher - MSN
Alnylam Pharmaceuticals Q1 2026 Earnings: AMVUTTRA Drives 153% TTR Revenue Growth and Pipeline Advances in RNAi Therapeutics 101551 - Minichart
Alnylam Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Alnylam Q1 2026 slides: historic $1B revenue milestone on ATTR-CM surge - Investing.com India
Earnings call transcript: Alnylam Q1 2026 sees record revenue, EPS beat - Investing.com Canada
Alnylam (ALNY) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
[10-Q] ALNYLAM PHARMACEUTICALS, INC. Quarterly Earnings Report - Stock Titan
Is Alnylam Pharmaceuticals (ALNY) Still 41.3% Undervalued After - GuruFocus
Pfizer deals extend patent life for a top-selling rare disease drug - Pharma Voice
ALNYLAM PHARMACEUTICALS ($ALNY) Releases Q1 2026 Earnings - Quiver Quantitative
Alnylam Reports Q1 2026: $1.17B Total Revenue, $1.036B Net Product Revenue, $206M Net Income - TradingView
Alnylam: Q1 Earnings Snapshot - KHOU
(ALNY) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress - Business Wire
H.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY) - The Globe and Mail
MSN Money - MSN
Vanguard (ALNY) holds 7.10M shares, 5.35% stake disclosed on Schedule 13G - Stock Titan
HC Wainwright & Co. Reiterates Alnylam Pharmaceuticals (ALNY) Buy Recommendation - MSN
Alnylam earnings up next: Can Amvuttra sustain momentum? By Investing.com - Investing.com Canada
Alnylam (ALNY) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Is It Too Late To Consider Alnylam Pharmaceuticals (ALNY) After Its Strong Multi‑Year Run? - simplywall.st
RNA Therapeutics Market is Going to Booming Growth 2026-2033| - openPR.com
Huntington’s Disease Pipeline Set for Breakthrough Transformation by 2026 with 20+ Therapies and Advancing Gene-Silencing Innovations | DelveInsight - Barchart.com
JP Morgan Maintains Alnylam Pharmaceuticals (ALNY) Overweight Recommendation - MSN
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Unpacking the 46.95% Potential Upside for Investors - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial - Insider Monkey
Alnylam announces proposed offering of $500M convertible senior notes - MSN
Do options traders know something about Alnylam Pharmaceuticals stock we don't? - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Teacher Retirement System of Texas - MarketBeat
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance - MSN
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TNYA pulls back after hours following significant $1.13B deal-spurred rally - MSN
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Bernstein SocGen cuts Alnylam stock price target on Amvuttra focus By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued (ALNY) - Seeking Alpha
Why Alnylam (ALNY) is Poised to Beat Earnings Estimates Again - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
ALNY Q4 earnings beat, sales miss despite Y/Y growth, stock down - MSN
Alnylam Pharmaceuticals (ALNY) Expected to Announce Earnings on Thursday - MarketBeat
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As Growth Momentum Cools After Multi Year Gains - simplywall.st
Alnylam Pharmaceuticals, Inc.Common Stock (NQ: ALNY - FinancialContent
Alnylam Pharmaceuticals (XTER:DUL) Short-term investments - GuruFocus
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Alnylam Pharmaceuticals (ALNY) presents Vutrisiran ATTR-CM data at ACC.26 - MSN
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today - Benzinga
Zurcher Kantonalbank Zurich Cantonalbank Buys 48,860 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
Truist Lowers PT on Alnylam Pharmaceuticals (ALNY) to $505 From $515 - Insider Monkey
0.73%
자본화:
|
볼륨(24시간):